Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose

Inger Hee Mathiesen, Mette Friberg Hitz, Terese Lea Katzenstein, Peter Oturai, Marianne Skov, Niklas Rye Jørgensen, Peter Oestrup Jensen, Christine Raaberg Mikkelsen, Rikke Krogh-Madsen, Tacjana Pressler, Daniel Faurholt-Jepsen

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


BACKGROUND: Cystic fibrosis(CF) related diabetes(CFRD) and osteoporosis are prevalent in adult patients with CF. We aimed to evaluate if CFRD and markers of glucose metabolism and inflammation are associated with bone turnover in CF.

METHODS: Cross sectional study at the adult section at the Copenhagen CF Center from January-October 2017. Fasting blood samples, including bone turnover markers(BTMs) and cytokines, Dual-x-ray absorptiometry scan and oral glucose tolerance test were performed. Lung-transplanted participants and patients in antiosteoporotic treatment were excluded from analyses.

RESULTS: 102 patients were included of whom 19 had a prior CFRD diagnosis. CFRD patients had lower procollagen type 1 N-terminal propeptide(P1NP) and C-Terminal cross-linked Telopeptide(CTX) levels compared to CF patients without diabetes (median[IQR]) 49.5 μg/l [29.6,57.1] vs 56.9 μg/l [38.2,74.3], p = .03 and 0.2 μg/l [0.1,0.3] vs 0.4 μg/l [0.3,0.6], p < .01, respectively. Fasting plasma glucose(FPG) was negatively associated with the bone formation markers P1NP and osteocalcin and bone resorption marker CTX. In multivariate linear regression FPG remained a significant predictor of P1NP -1.07 [-1.09;-0.01] and CTX -1.13 [-1.21;-1.06]. Bone mineral density Z-score was not different between patients with and without CFRD but FPG was negatively associated with hip and femoral neck Z-score. There was no consistent association between inflammatory cytokines and BTMs.

CONCLUSIONS: Bone turnover markers are reduced in CF patients with CFRD and negatively associated with glucose levels. Extra attention towards frequent hyperglycemia in CF patients should be taken when evaluating decreased BMD. Glycemia may be a future target for improving outcome in CFBD.

Sider (fra-til)436-441
Antal sider6
TidsskriftJournal of Cystic Fibrosis
Udgave nummer3
StatusUdgivet - maj 2019

Bibliografisk note

Copyright � 2019. Published by Elsevier B.V.


Udforsk hvilke forskningsemner 'Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose' indeholder.